Cbz-Dap-OH·HCl

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cbz-Dap-OH·HCl
• 英文别名: 3-amino-(2S)-benzyloxycarbonylamino propionic acid hydrochloride；(2S)-3-amino-2-(phenylmethoxycarbonylamino)propanoic acid;hydrochloride
• 化学式: C₁₁H₁₄N₂O₄*ClH
• 分子量: 274.704
• InChiKey: DCTMDVFOSUZFEN-FVGYRXGTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.39
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Cbz-Dap-OH·HCl 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 3-氨基-N-(苄氧基羰基)-L-丙氨酸甲酯
  参考文献：
  名称：

  Inhibitors or bone reabsorption and antagonists of vitronectin receptors

  摘要：

  新型骨吸收抑制剂和维脱内钙受体拮抗剂本发明涉及公式I的5-成员环杂环化合物，其中E、F、G、W、Y和Z的含义如专利要求中所述，以及它们的制备和用作药物的用途。这些新型化合物被用作维脱内钙受体拮抗剂和骨吸收抑制剂。

  公开号：

  US06218415B1
• 作为产物：
  描述：

  N-苄氧羰酰基-L-丝氨酸甲酯 在 盐酸 、 三(2-氯乙基)胺 、 硫化氢 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 苯 为溶剂， 反应 26.5h， 生成 Cbz-Dap-OH·HCl
  参考文献：
  名称：

  Golding, Bernard T.; Howes, Colin, Journal of Chemical Research, Miniprint, 1984, # 1, p. 101 - 110

  摘要：

  DOI：

文献信息

• Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
  申请人：——

  公开号：US20010021708A1

  公开（公告）日：2001-09-13

  The present invention relates to 5-membered ring heterocycles of the formula I, 1 in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments. The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

  本发明涉及公式I中的5元环杂环，其中E、F、G、W、Y和Z具有专利要求中给出的含义，以及它们的制备和用作药物的方法。这些新化合物用作vitronectin受体拮抗剂和骨吸收抑制剂。
• Ether derivative
  申请人：Okuzumi Tatsuya

  公开号：US20060270693A1

  公开（公告）日：2006-11-30

  The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

  本发明涉及一种以式(I)表示的醚衍生物，其药学上可接受的盐、水合物或溶剂化物，其中每个符号如描述中所定义的，并且一种以式(III)表示的醚衍生物，其药学上可接受的盐、水合物或溶剂化物，其中每个符号如描述中所定义的；一种含有该醚衍生物的制药组合物；以及一个包含该制药组合物及其使用说明的包装。本发明的制药组合物，包含该化合物具有优异的抗炎和镇痛活性，并且可用作各种药物剂型，如抗炎剂、镇痛剂、治疗炎症性肠病的治疗剂、治疗排尿过频和/或失禁的治疗剂、治疗哮喘等。
• Inhibitors of bone reabsorption and antagonists of vitronectin receptors
  申请人：Hoechst Aktiengesellschaft

  公开号：US06620820B2

  公开（公告）日：2003-09-16

  The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments. The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

  本发明涉及公式I的5元环杂环，其中E、F、G、W、Y和Z具有专利要求中给定的含义，以及它们的制备和用作药物的用途。新化合物用作玻璃蛋白受体拮抗剂和骨吸收抑制剂。
• ETHER DERIVATIVE
  申请人：Ajinomoto Co., Inc.

  公开号：EP1679296A1

  公开（公告）日：2006-07-12

  The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

  本发明涉及一种由式（I）表示的醚衍生物、其药学上可接受的盐、其水合物或其溶液 其中各符号如描述中所定义，以及由式（III）表示的醚衍生物、其药学上可接受的盐、其水合物或其溶物 其中各符号在说明中定义；含有醚衍生物的药物组合物；以及含有药物组合物及其使用说明的包装。含有本发明化合物的本发明药物组合物具有优异的抗炎和镇痛活性，可用作各种药物制剂，如抗炎剂、镇痛剂、炎症性肠病治疗剂、花粉尿症和/或失禁治疗剂、哮喘治疗剂等。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2015035102A3

  公开（公告）日：2015-10-29